Literature DB >> 21689618

Conventional Surgical Treatment of Hepatocellular Carcinoma.

T Mark Earl1, William C Chapman.   

Abstract

Liver resection remains the standard therapy for solitary hepatocellular carcinoma in patients with preserved hepatic function. In well-selected patients, 5-year survival rates are good and can approach that of liver transplantation for early-stage disease. Patient selection is critical to optimizing therapeutic benefit, and the health of the native liver must be considered in addition to tumor characteristics. Hepatic recurrence after resection is common. The difficulty lies in deciding which patients with chronic liver disease and small solitary tumors are best served by resection and which should proceed with transplant evaluation; this is the focus of this article.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21689618     DOI: 10.1016/j.cld.2011.03.008

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  8 in total

1.  Using ALPPS to induce rapid liver hypertrophy in a patient with hepatic fibrosis and portal vein thrombosis.

Authors:  Keith M Cavaness; M B Majella Doyle; Yiing Lin; Erin Maynard; William C Chapman
Journal:  J Gastrointest Surg       Date:  2012-09-21       Impact factor: 3.452

Review 2.  Resection for hepatocellular carcinoma.

Authors:  Hariharan Ramesh
Journal:  J Clin Exp Hepatol       Date:  2014-08-27

3.  Could radiofrequency ablation replace liver resection for small hepatocellular carcinoma in patients with compensated cirrhosis? A 5-year follow-up.

Authors:  Jacopo Desiderio; Stefano Trastulli; Rosario Pasquale; Davide Cavaliere; Roberto Cirocchi; Carlo Boselli; Giuseppe Noya; Amilcare Parisi
Journal:  Langenbecks Arch Surg       Date:  2012-12-07       Impact factor: 3.445

Review 4.  Particle therapy for cancers: a new weapon in radiation therapy.

Authors:  Guo-Liang Jiang
Journal:  Front Med       Date:  2012-05-09       Impact factor: 4.592

5.  Potential enhancement of intravenous nano-hydroxyapatite in high-intensity focused ultrasound ablation for treating hepatocellular carcinoma in a rabbit model.

Authors:  Liping Liu; Ziwen Xiao; Yanbing Xiao; Zhibiao Wang; Faqi Li; Maoping Li; Xiaoqiong Peng
Journal:  Oncol Lett       Date:  2014-02-21       Impact factor: 2.967

6.  Diagnostic utility of plasma lncRNA small nucleolar RNA host gene 1 in patients with hepatocellular carcinoma.

Authors:  Shoubao Gao; Xiaohong Xu; Yue Wang; Wei Zhang; Xingye Wang
Journal:  Mol Med Rep       Date:  2018-07-30       Impact factor: 2.952

7.  Case Report: Combining liver partition and portal vein ligation after thrombectomy for tumor isolation (CLAPT) to treat advanced hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Zongrui Jin; Guolin Wu; Banghao Xu; Jilong Wang; Hai Zhu; Ya Guo; Minhao Peng; Tao Peng; Zhang Wen
Journal:  Front Surg       Date:  2022-09-13

8.  X-inactive-specific transcript of peripheral blood cells is regulated by exosomal Jpx and acts as a biomarker for female patients with hepatocellular carcinoma.

Authors:  Xiang Ma; Tingdong Yuan; Chao Yang; Zusen Wang; Yunjin Zang; Liqun Wu; Likun Zhuang
Journal:  Ther Adv Med Oncol       Date:  2017-09-21       Impact factor: 8.168

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.